When people with infectious tuberculosis (TB) cough, sneeze or otherwise exhale droplets, they expose others to Mycobacterium tuberculosis. After a person is exposed, they can be infected with M. tuberculosis without having TB disease and without signs and symptoms. This is called latent TB infection (LTBI).
Childhood immunisation against S. pneumoniae is the most effective public health measure for preventing IPD both among vaccine recipients (direct effect), and among unimmunised populations (indirect ‘herd’ effect).
Public health advice on prevention of diarrhoeal illness with special focus on Shiga toxin - producing Escherichia coli (STEC), also called verotoxin - producing E. coli (VTEC) or enterohaemorrhagic E. coli (EHEC)
EU case definition for diarrhoea and haemolytic uremic syndrome (HUS) caused by the epidemic strain Shiga toxin 2-producing Escherichia Coli (STEC) O104:H4
Outbreak of Shiga toxin - producing Escherichia coli (STEC), also called verotoxin-producing E. coli (VTEC) or enterohaemorrhagic E. coli (EHEC) in 2011
In EU, only 1 in every 3 MDR TB patients has a successful treatment outcome; more than half either die, fail treatment or default (stop taking treatment). XDR TB has even worse treatment outcomes: only 1 in 4 patients finishes treatment successfully.
Immunisation is the only effective method of prevention. Mumps vaccine is given in the form of the combined trivalent measles-mumps-rubella (MMR) vaccine in all European countries with a first dose at or before 18 months of age. The timing of the second dose varies across countries.